<DOC>
	<DOC>NCT01959230</DOC>
	<brief_summary>To compare the efficacy and safety of brimonidine tartrate ophthalmic solution 0.025% with its vehicle for treating ocular redness in a population of adult and geriatric participants with ocular redness.</brief_summary>
	<brief_title>Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects With Ocular Redness.</brief_title>
	<detailed_description />
	<mesh_term>Hyperemia</mesh_term>
	<mesh_term>Erythema</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>At least 18 years of age. Have a history of redness relief drops use, or expressed a desire to use drops for redness relief, within the last 6 months. Have ocular health within normal limits including a calculated bestcorrected visual acuity of 0.3 logMAR or better in each eye, as measured using an ETDRS chart. Any ocular/systemic health problems. Use of any disallowed medications.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Ocular redness</keyword>
</DOC>